12 results on '"Ayling H"'
Search Results
2. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
- Author
-
Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, Barbosa ER, Bonifati V, Quinn NP, Abou-Sleiman P, Wood NW, Petrie A, Sampaio C, Ferreira JJ, Holton J, Revesz T, Lees AJ, Silveira-Moriyama, L, Guedes, L C, Kingsbury, A, and Ayling, H
- Published
- 2008
- Full Text
- View/download PDF
3. The effects of oral nutritional interventions combined with physical activity on nutritional and functional outcomes in the management of malnutrition: a systematic review
- Author
-
Ayling, H., primary and Baldwin, C., additional
- Published
- 2012
- Full Text
- View/download PDF
4. The Activity Coefficients of Some Bivalent Metal Nitrates in Aqueous Solution at 25° from Isopiestic Vapor Pressure Measurements
- Author
-
Robinson, R. A., primary, Wilson, Jean M., additional, and Ayling, H. S., additional
- Published
- 1942
- Full Text
- View/download PDF
5. External Noninvasive Peripheral Nerve Stimulation Treatment of Neuropathic Pain: A Prospective Audit.
- Author
-
Johnson S, Ayling H, Sharma M, and Goebel A
- Subjects
- Female, Follow-Up Studies, Humans, Male, Pain Measurement, Prospective Studies, Treatment Outcome, Complex Regional Pain Syndromes psychology, Complex Regional Pain Syndromes therapy, Electric Stimulation Therapy methods, Neuralgia psychology, Neuralgia therapy
- Abstract
Background: Peripheral nerve stimulation (PNS) is a neuromodulation technique in which electrical current is applied to the peripheral nerves to ameliorate chronic pain through preferential activation of myelinated fibres, inducing long-term depression of synaptic efficacy. External noninvasive peripheral nerve stimulation (EN-PNS) is a novel and simple form of PNS that involves stimulation via an external nerve-mapping probe that is placed on the skin and connected to a power source., Objectives: We aimed to assess the clinical utility of EN-PNS in patients with refractory neuropathic pains referred to a tertiary pain treatment center., Methods: We undertook a prospective audit of EN-PNS. Patients with a diagnosis of either complex regional pain syndrome or neuropathic pain after peripheral nerve injury who met inclusion criteria were included. Participants completed three stages of the audit: stage 1, six weekly outpatient treatment sessions; stage 2, six-week equipment home loan; stage 3, six weeks of no EN-PNS treatment. The primary outcome was the average post-treatment instantaneous pain intensity during the last week in stage 2 compared with baseline (11-point numerical rating scale)., Results: EN-PNS provided significant short-term pain relief (n = 20 patients, average reduction of 2.8 numerical rating scale points, 95% CI 1.6-4.0, p < 0.001, intention-to-treat analysis). Eight patients (40%) improved in several outcome parameters ("responders"), including quality of life and function., Conclusion: In this first prospective report on the use of EN-PNS in neuropathic pain, this technology provided significant clinical benefit for some patients. Controlled studies are required to confirm our results and the place of EN-PNS in future neuromodulation treatment algorithms. Given the refractory nature of these conditions, these results are encouraging., (© 2014 International Neuromodulation Society.)
- Published
- 2015
- Full Text
- View/download PDF
6. A novel prion disease associated with diarrhea and autonomic neuropathy.
- Author
-
Mead S, Gandhi S, Beck J, Caine D, Gallujipali D, Carswell C, Hyare H, Joiner S, Ayling H, Lashley T, Linehan JM, Al-Doujaily H, Sharps B, Revesz T, Sandberg MK, Reilly MM, Koltzenburg M, Forbes A, Rudge P, Brandner S, Warren JD, Wadsworth JDF, Wood NW, Holton JL, and Collinge J
- Subjects
- Animals, Autonomic Nervous System Diseases pathology, Female, Humans, Longitudinal Studies, Male, Mice, Mice, Transgenic, Mutation, Pedigree, Phenotype, Plaque, Amyloid pathology, Prion Diseases complications, Prion Diseases pathology, Prion Diseases transmission, Prion Proteins, Autonomic Nervous System Diseases etiology, Brain pathology, Diarrhea etiology, Prion Diseases genetics, Prions genetics
- Abstract
Background: Human prion diseases, although variable in clinicopathological phenotype, generally present as neurologic or neuropsychiatric conditions associated with rapid multifocal central nervous system degeneration that is usually dominated by dementia and cerebellar ataxia. Approximately 15% of cases of recognized prion disease are inherited and associated with coding mutations in the gene encoding prion protein (PRNP). The availability of genetic diagnosis has led to a progressive broadening of the recognized spectrum of disease., Methods: We used longitudinal clinical assessments over a period of 20 years at one hospital combined with genealogical, neuropsychological, neurophysiological, neuroimaging, pathological, molecular genetic, and biochemical studies, as well as studies of animal transmission, to characterize a novel prion disease in a large British kindred. We studied 6 of 11 affected family members in detail, along with autopsy or biopsy samples obtained from 5 family members., Results: We identified a PRNP Y163X truncation mutation and describe a distinct and consistent phenotype of chronic diarrhea with autonomic failure and a length-dependent axonal, predominantly sensory, peripheral polyneuropathy with an onset in early adulthood. Cognitive decline and seizures occurred when the patients were in their 40s or 50s. The deposition of prion protein amyloid was seen throughout peripheral organs, including the bowel and peripheral nerves. Neuropathological examination during end-stage disease showed the deposition of prion protein in the form of frequent cortical amyloid plaques, cerebral amyloid angiopathy, and tauopathy. A unique pattern of abnormal prion protein fragments was seen in brain tissue. Transmission studies in laboratory mice were negative., Conclusions: Abnormal forms of prion protein that were found in multiple peripheral tissues were associated with diarrhea, autonomic failure, and neuropathy. (Funded by the U.K. Medical Research Council and others.).
- Published
- 2013
- Full Text
- View/download PDF
7. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model.
- Author
-
Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, Sterlacci W, Maeir H, Poewe W, and Lees AJ
- Subjects
- Aged, Brain Stem metabolism, Female, Humans, Immunohistochemistry, Lewy Bodies metabolism, Lewy Bodies pathology, Lewy Body Disease pathology, Male, Middle Aged, Neurons metabolism, Odds Ratio, Parkinson Disease metabolism, Severity of Illness Index, Tyrosine 3-Monooxygenase metabolism, alpha-Synuclein metabolism, Brain Stem pathology, Neurons pathology, Parkinson Disease pathology
- Abstract
The lower brain stem of 25 pathologically-confirmed Parkinson's disease (PD) cases was examined by alpha synuclein immunohistochemistry to characterize pathological accumulation of alpha synuclein (Lewy-type α-synucleinopathy, LTS) in the medulla oblongata, to examine differences between affected regions and test a proposed model of staging of pathology in PD. All cases had LTS in the medulla, including the dorsal motor nucleus of the vagus (dmX), when present. The distribution followed a consistent pattern and appeared to be concentrated in a tyrosine hydroxylase (TH) immunoreactive region, probably representing the dorsal IX/X nuclear complex and the intermediate reticular zone. LTS density was greatest in the dmX. A similar distribution pattern to PD was seen in 14 incidental Lewy body disease (ILBD) cases, five derived from the Queen Square Brain Bank tissue collection and nine identified in separate series of 60 neurologically-normal individuals, and in three cases with the G2019S mutation of LRRK2. Semiquantitative assessment showed that severity of pathology in the dmX was not correlated with the severity of cortical pathology. Semiquantitative assay of TH and ChAT peptide expression in the medulla showed that TH expression in PD and ILBD did not differ from controls. These findings broadly support the Braak hypothesis of caudo-rostral development but indicate that the extent of the disease in the cortex and the severity of pathology in the medulla were independent of one another., (© 2010 Movement Disorder Society.)
- Published
- 2010
- Full Text
- View/download PDF
8. Hyposmia in progressive supranuclear palsy.
- Author
-
Silveira-Moriyama L, Hughes G, Church A, Ayling H, Williams DR, Petrie A, Holton J, Revesz T, Kingsbury A, Morris HR, Burn DJ, and Lees AJ
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Humans, Male, Mental Status Schedule, Middle Aged, Nerve Degeneration etiology, Nerve Degeneration pathology, Olfactory Pathways pathology, Olfactory Pathways physiopathology, ROC Curve, Retrospective Studies, Olfaction Disorders etiology, Smell physiology, Supranuclear Palsy, Progressive complications
- Abstract
Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP., ((c) 2010 Movement Disorder Society.)
- Published
- 2010
- Full Text
- View/download PDF
9. Regional differences in the severity of Lewy body pathology across the olfactory cortex.
- Author
-
Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W, Poewe W, Maier H, Lees AJ, and Revesz T
- Subjects
- Analysis of Variance, Autopsy, Entorhinal Cortex chemistry, Frontal Lobe chemistry, Humans, Immunohistochemistry, Substantia Nigra chemistry, Lewy Body Disease pathology, Olfactory Pathways chemistry, Parkinson Disease pathology, alpha-Synuclein analysis
- Abstract
We studied alpha-synuclein pathology in the rhinencephalon of ten cases of Parkinson's disease (PD) and twelve neurologically normal controls, of which seven had incidental Lewy bodies in the substantia nigra at autopsy and five had no pathological evidence of neurological disease. In all PD and incidental Lewy bodies cases, alpha-synuclein pathology was found in all five subregions of the primary olfactory cortex that were sampled, and amongst them the pathology was significantly more severe in the temporal division of the piriform cortex than in the frontal division of the piriform cortex, olfactory tubercle or anterior portions of the entorhinal cortex. The orbitofrontal cortex, which is an area of projection from the primary olfactory cortex, was affected in some cases but overall the alpha-synuclein pathology was less severe in this area than in the primary olfactory cortex. Because different areas of the rhinencephalon are likely to play different roles in olfaction and our data indicate a differential involvement by alpha-synuclein deposition of structures implicated in smell, future prospective studies investigating the pathophysiological basis of hyposmia in PD should consider to examine the areas of primary olfactory cortex separately.
- Published
- 2009
- Full Text
- View/download PDF
10. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta.
- Author
-
Holton JL, Lashley T, Ghiso J, Braendgaard H, Vidal R, Guerin CJ, Gibb G, Hanger DP, Rostagno A, Anderton BH, Strand C, Ayling H, Plant G, Frangione B, Bojsen-Møller M, and Revesz T
- Subjects
- Adult, Amyloidosis pathology, Antigens, CD metabolism, Antigens, Differentiation, Myelomonocytic metabolism, Benzothiazoles, Blood Vessels metabolism, Brain Diseases pathology, Coloring Agents, Congo Red, Dementia pathology, Denmark, Female, Fluorescent Dyes, Glial Fibrillary Acidic Protein metabolism, Histocompatibility Antigens Class II metabolism, Humans, Immunoblotting, Immunohistochemistry, Male, Microscopy, Electron, Microscopy, Immunoelectron, Middle Aged, Pedigree, Staining and Labeling, Thiazoles, tau Proteins metabolism, Amyloid beta-Peptides metabolism, Amyloidosis metabolism, Brain Diseases metabolism, Dementia genetics, Dementia metabolism
- Abstract
Familial Danish dementia (FDD) is pathologically characterized by widespread cerebral amyloid angiopathy (CAA), parenchymal protein deposits, and neurofibrillary degeneration. FDD is associated with a mutation of the BRI2 gene located on chromosome 13. In FDD there is a decamer duplication, which abolishes the normal stop codon, resulting in an extended precursor protein and the release of an amyloidogenic fragment, ADan. The aim of this study was to describe the major neuropathological changes in FDD and to assess the distribution of ADan lesions, neurofibrillary pathology, glial, and microglial response using conventional techniques, immunohistochemistry, confocal microscopy, and immunoelectron microscopy. We showed that ADan is widely distributed in the central nervous system (CNS) in the leptomeninges, blood vessels, and parenchyma. A predominance of parenchymal pre-amyloid (non-fibrillary) lesions was found. Abeta was also present in a proportion of both vascular and parenchymal lesions. There was severe neurofibrillary pathology, and tau immunoblotting revealed a triplet electrophoretic migration pattern comparable with PHF-tau. FDD is a novel form of CNS amyloidosis with extensive neurofibrillary degeneration occurring with parenchymal, predominantly pre-amyloid rather than amyloid, deposition. These findings support the notion that parenchymal amyloid fibril formation is not a prerequisite for the development of neurofibrillary tangles. The significance of concurrent ADan and Abeta deposition in FDD is under further investigation.
- Published
- 2002
- Full Text
- View/download PDF
11. Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia.
- Author
-
Holton JL, Ghiso J, Lashley T, Rostagno A, Guerin CJ, Gibb G, Houlden H, Ayling H, Martinian L, Anderton BH, Wood NW, Vidal R, Plant G, Frangione B, and Revesz T
- Subjects
- Adaptor Proteins, Signal Transducing, Amyloid immunology, Antibodies, Monoclonal analysis, Antibodies, Monoclonal immunology, Antigens, CD analysis, Antigens, Differentiation, Myelomonocytic analysis, Benzothiazoles, Blood Vessels chemistry, Blood Vessels pathology, Central Nervous System pathology, Central Nervous System ultrastructure, Congo Red, Glial Fibrillary Acidic Protein analysis, Heredodegenerative Disorders, Nervous System pathology, Humans, Immunoblotting, Immunohistochemistry methods, Membrane Glycoproteins, Membrane Proteins, Microscopy, Immunoelectron, Peptide Fragments immunology, Staining and Labeling methods, Thiazoles, tau Proteins analysis, Amyloid metabolism, Central Nervous System chemistry, Heredodegenerative Disorders, Nervous System metabolism, Peptide Fragments metabolism
- Abstract
Familial British dementia (FBD), pathologically characterized by cerebral amyloid angiopathy (CAA), amyloid plaques, and neurofibrillary degeneration, is associated with a stop codon mutation in the BRI gene resulting in the production of an amyloidogenic fragment, amyloid-Bri (ABri). The aim of this study was to assess the distribution of ABri fibrillar and nonfibrillar lesions and their relationship to neurofibrillary pathology, astroglial and microglial response using immunohistochemistry, confocal microscopy, and immunoelectron microscopy in five cases of FBD. Abnormal tau was studied with immunoblotting. We present evidence that ABri is deposited throughout the central nervous system in blood vessels and parenchyma where both amyloid (fibrillar) and pre-amyloid (nonfibrillar) lesions are formed. Ultrastructurally amyloid lesions appear as bundles of fibrils recognized by an antibody raised against ABri, whereas Thioflavin S-negative diffuse deposits consist of amorphous electron-dense material with sparse, dispersed fibrils. In contrast to nonfibrillar lesions, fibrillar ABri is associated with a marked astrocytic and microglial response. Neurofibrillary tangles and neuropil threads occurring mainly in limbic structures, are found in areas affected by all types of ABri lesions whereas abnormal neurites are present around amyloid lesions. Immunoblotting for tau revealed a triplet electrophoretic migration pattern. Our observations confirm a close link between ABri deposition and neurodegeneration in FBD.
- Published
- 2001
- Full Text
- View/download PDF
12. Blessed respite.
- Author
-
Ayling H
- Subjects
- Aged, Community Participation, Humans, United Kingdom, Health Services Needs and Demand, Respite Care
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.